Parmax Pharma Limited reported unaudited standalone earnings results for second quarter and six months ended September 30, 2018. For the quarter, the company’s revenue from operations was INR 35,350,685 against INR 33,719,949 a year ago. Total income was INR 35,395,001 against INR 33,764,320 a year ago. Loss from operations before exceptional items and tax was INR 5,544,761 against INR 1,100,778 a year ago. Loss before tax was 5,544,761 against INR 1,100,778 a year ago. Net loss from continuing operations of INR 5,544,761 or INR 1.48 per basic share against INR 1,100,778 or INR 0.29 per basic share a year ago. Loss of INR 5,544,761 or INR 1.48 per basic share against INR 1,100,778 or INR 0.29 per share a year ago. For the six months, the company’s revenue from operations was INR 69,178,127 against INR 59,781,662 a year ago. Total income was INR 69,265,037 against INR 60,026,913 a year ago. Loss from operations before exceptional items and tax was INR 4,930,625 against INR 3,192,290 a year ago. Loss before tax was 4,930,625 against INR 3,192,290 a year ago. Net loss from continuing operations of INR 4,930,625 or INR 1.32 per basic share against INR 3,192,290 or INR 0.85 per basic share a year ago. Loss of INR 4,930,625 or INR 1.32 per basic share against INR 3,192,290 or INR 0.85 per share a year ago.